Clarification of Scope. For the avoidance of any doubt whatsoever, Bionics and the Company acknowledge and agree that the terms “neuromodulation” and “neuro- related” (as used in any of the Amended Documents) do not include, and in no event does any license granted to Bionics under the Development Agreement or the License Agreement relate to, cardiac applications.
Clarification of Scope. This section lists and describes threats to the IT product that are not countered by the evaluated security functions of the product. It may occur that some clients will assume that some threats are being met by the IT product but in fact they are not. It is for these reasons that these uncountered threats should be listed for clarification. It would however, be impractical to list all possible threats that cannot be countered by an individual product.
Clarification of Scope. The scope and class of work set out above shall not encroach upon the core work and skills of electrical operatives graded and employed under the JIB National Working Rules. Skilled JIB Graded Electrical Operatives who have been suitably trained for the purpose will carry out the containment carcass and supporting structure work other than as required for dedicated in-scope work defined in 6.2 which may be carried out by Datacomms Operatives.
Clarification of Scope. For clarity, the commercial distribution rights for the Product in the Territory, and scope of the licenses granted under Section 2.2, are limited to the Product and Laboratory Licenses, and [*] is subject to the [*] in this Agreement. QIAGEN acknowledges and agrees that Xxxxxx shall at all times retain the right to: (i) perform [*] [*], including on the Sequencing System, as part of its laboratory developed test (“LDT”) offerings in laboratories owned by Xxxxxx and its Affiliates, and (ii) subject to fulfilling the obligations in Section 4.1, below, develop and commercialize an [*] for use on a different sequencing system (i.e. other than QIAGEN’s Gene Reader® [*] Sequencer) as an LDT or subject to Section 3.1.2, as an IVD and to partner with one or more third parties in connection therewith.
Clarification of Scope. For the avoidance of doubt, the purpose of this Article 3 is to compensate TGC with respect to Celladon Products only. TGC acknowledges and agrees that TGC is not entitled to any compensation received by Celladon, its Affiliates and/or their respective shareholders for the disposition (by asset sale, license, spin-out, or otherwise) of any Celladon assets that are not related to Celladon Products in transactions that are not Sale Transactions, and Celladon shall at all times be free, at its sole discretion, to dispose of such assets unrelated to Celladon Products in any manner, without obligation to TGC (unless such disposition occurs as part of a Sale Transaction, in which case Section 3.3(c) shall apply).
